We were fortunate to meet with MDS Congress Scientific Program Committee member, Antonio Strafella (Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada) who spoke to us about imaging biomarkers of cognitive decline in Parkinson’s disease.
Questions
1. What is known about the pathological processes underlying cognitive decline in Parkinson’s disease (PD)? (0:05)
2. What neuroimaging biomarkers appear useful in this setting? (1:40)
3. What are the most promising CSF biomarkers of cognitive decline in PD? (3:18)
4. What genetic factors affect the risk of cognitive decline in patients with PD? (4:17)
5. What further research is needed before these biomarkers enter clinical use? (5:44)
Speaker disclosure: Antonio P Strafella has received funding from the Canada Research Chairs Program (CRCP), Canadian Institutes of Health Research (CIHR), National Parkinson Foundation (NPF), Parkinson Disease Foundation (PDF), Parkinson Canada, Ontario Gambling Association, Tourette Syndrome Association (TSA), Brain Canada, Weston Brain Institute, and honoraria from GE Healthcare Canada Ltd.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
